Clinical trial
Neoadjuvant GW572016 to Treat Breast Cancer
NCT00206427 · Baylor Breast Care Center, Other · Completed
Key facts
| NCT number | NCT00206427 |
|---|---|
| Title | Neoadjuvant GW572016 to Treat Breast Cancer |
| Official title | A Neoadjuvant Phase II Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients: Biologic Correlative Study |
| Acronym | GW |
| Lead sponsor | Baylor Breast Care Center, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | GW572016, lapatinib |
| Enrollment | 49 |
| Start date | Aug 1, 2004 |
| Primary completion | Jun 1, 2011 |
| Completion | Feb 1, 2012 |
| First posted | Sep 21, 2005 |
| Last update posted | Sep 29, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: